Fintel reports that on May 27, 2025, BTIG downgraded their outlook for Globus Medical (NYSE:GMED) from Buy to Neutral.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.5, a high ...

BTIG analysts have downgraded (NYSE:GMED) from "Buy" to "Neutral" amid fears surrounding the company's Spine business.

On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns ...

Globus Medical (NYSE:GMED) announced that its board of directors authorized a share repurchase program totaling up to $500 ...

Globus Medical’s first quarter of 2025 proved challenging, with results falling below expectations. The company attributed this underperformance to delays in Enabling Technology deals ...

Globus Medical, Inc. has a 1 year low of $54.48 and a 1 year high of $94.93. The firm has a 50 day moving average price of $69.35 and a 200 day moving average price of $78.83.

How Do Unusual Items Influence Profit? To properly understand Globus Medical's profit results, we need to consider the US$200m expense attributed to unusual items. While deductions due to unusual ...

We'll examine a selection from our screener results. Overview: Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for musculoskeletal disorders ...

From new partnerships and launches, here are six developments from Globus Medical so far in 2025. 1. OsteoCentric Technologies entered into a non-exclusive licensing agreement with Globus Medical.

Globus Medical’s first quarter of 2025 proved challenging, with results falling below expectations. The company attributed this underperformance to delays in Enabling Technology deals, temporary ...